Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8823455 | 0.99 | MEN1 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL9390499 | 0.89 | MEN1 (0.54) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL8823462 | 0.89 | MEN1 (0.54) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL9443640 | 0.89 | MEN1 (0.54) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL10338646 | 0.89 | SIRT2 (0.60) | SIRT2ITGB3ITGA2BSIRT1SIRT3 | |
| SCHEMBL25408743 | 0.88 | EPHX2 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL30910821 | 0.88 | EPHX2 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL30910825 | 0.88 | EPHX2 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL28252274 | 0.88 | MEN1 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 | |
| SCHEMBL28252275 | 0.88 | MEN1 (0.52) | MEN1KMT2AFAAHEPHX2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | Merck, Sharp & Dohme LLC (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | MEN1 2445/4885KMT2A 3489/4885FAAH 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.